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Abstract: A novel and integral approach to the understanding of human neurodegenerative 
diseases (HNDDs) and cancer based upon the disruption of the intracellular dynamics of the 
hydrogen ion (H+) and its physiopathology, is advanced. From an etiopathological perspective, 
the activity and/or deﬁ  ciency of different growth factors (GFs) in these pathologies are studied, 
and their relationships to intracellular acid-base homeostasis reviewed. Growth and trophic 
factor withdrawal in HNDDs indicate the need to further investigate the potential utilization 
of certain GFs in the treatment of Alzheimer disease and other neurodegenerative diseases. 
Platelet abnormalities and the therapeutic potential of platelet-derived growth factors in these 
pathologies, either through platelet transfusions or other clinical methods, are considered. 
Finally, the etiopathogenic mechanisms of apoptosis and antiapoptosis in HNDDs and cancer 
are viewed as opposite biochemical and biological disorders of cellular acid-base balance and 
their secondary effects on intracellular signaling pathways and aberrant cell metabolism are 
considered in the light of the both the seminal and most recent data available. The “trophic factor 
withdrawal syndrome” is described for the ﬁ  rst time in English-speaking medical literature, as 
well as a Darwinian-like interpretation of cellular behavior related to speciﬁ  c and nonspeciﬁ  c 
aspects of cell biology.
Keywords: neurodegenerative diseases and growth factors; Alzheimer’s Disease, human 
neurodegenerative diseases, cancer, intracellular acid-base homeostasis, apoptosis, antiapoptosis, 
etiopathogenesis and treatment
“We can only cure what we can understand ﬁ  rst”
Otto Warburg
Introduction
Modern medicine faces an almost total lack of success both in the prevention and treatment 
of human neurodegenerative diseases (HNDDs), like Alzheimer’s disease (AD), multiple 
sclerosis (MS), amyotrophic lateral sclerosis (ALS), Hungtington’s disease (HD), retinitis 
pigmentosa (RP), and others. Symptomatic treatments are available for other processes, 
such as Parkinson’s disease (PD). The main problem seems to lie in the fact that it has not 
been so far possible to prevent, stop or reverse the premature and spontaneous process of 
progressive cell death or programmed cell death (PCD) via apoptosis or related mecha-
nisms in HNDDs (paraptosis, autophagy, etc) (Harguindey et al 2007). New conceptual 
approaches appear most necessary in order to discover novel therapies for the prevention Neuropsychiatric Disease and Treatment 2008:4(6) 1074
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and treatment of these processes (Sperandio et al 2000; 
Lagadic-Gossman et al 2004; Bröcker et al 2005).
Attempts to advance an integral and unifying hypoth-
esis on the etiopathogenesis of HNDDs have been pro-
posed for decades. This has mainly focused on the lack 
in growth factor (GF) stimulation, mainly on deﬁ  ciencies 
in nerve growth factor (NGF) (Appel 1983; Hefti 1983; 
Schultze-Herbrüggen et al 2008). PCD in HNDDs, either 
apoptosis-mediated or not, can be induced either by: A) 
Depletion, spontaneous or induced, of different GFs, either 
from neural origin or otherwise (trophic factor withdrawal, 
or TFW) (Rebollo et al 1995; Khaled et al 2001; Tatton 
et al 2002; Resnick et al 2004), and/or B) The activation 
or overexpression of mechanisms that stimulate PCD (ie, 
caspases, etc.), which can also be secondary to TFW-medi-
ated mechanisms (Sperandio et al 2000; Tatton et al 2002; 
Liu et al 2004; Lavrik et al 2005; Riedl et al 2005). While 
acting upon mechanism B is to a great deal still controver-
sial, mechanism A can be to a certain extent counteracted 
through the therapeutic utilization of a wide array of trophic 
and/or human GFs in order to control and/or even suppress 
pathological cell death programs (PCDP). The utilization of 
GFs, besides preventing cell death, is used to stimulate cell 
growth and proliferation in a wide array of clinical settings 
in modern clinical practice (Table 1) (Varon 1981; Barbin 
1987; Khaled et al 2001; Tatton et al 2002; Anitua et al 2004, 
2007b; Anitua 2005). Recently, several plasma signaling 
proteins have been found to be signiﬁ  cantly deﬁ  cient even 
in preclinical and asymptomatic stages of AD, revealing a 
decrease in the circulation of different hematopoiesis-depen-
dent GFs, like platelet-derived growth factor (PDGF), trans-
forming growth factor-1 (TGF-1), epidermal growth factor 
(EGF), vascular endothelial growth factor (VEGF), basic 
ﬁ  broblast growth factor (bFGF), hepatocyte growth factor 
(HGF), etc., in this disease (Ray et al 2007). Since several 
of them, like PDGF, TGF-1, EGF, VEGF, bFGF, HGF, 
bone morphogenetic protein-2 (BMP-2), -4, -6, connective 
tissue growth factor (CTGF), etc. (Table 2) (Anitua et al 
2004; Kut et al 2007), are contained in high concentrations 
in young functional platelets and/or leukocytes, it becomes 
surprising that while highly sophisticated methods are being 
investigated to induce and increase the activity of a cohort of 
growth factors, either from neural origin or not, in different 
models of HNDDs (Storkebaum et al 2004; Vende Velde 
et al 2005; Wagner et al 2006), at least to our knowledge 
no previous mention has been made on the possibility of 
using young and healthy platelets and, perhaps to a lesser 
degree, leukocyte transfusions, their most widespread natural 
source, in the treatment of certain HNDDs. The apparent 
lack of speciﬁ  city in the stimulation of tissue regeneration 
Table 1 Use of platelet-based technology in modern clinical medicine
Objective Results References
Gastric ulcer healing Treatment with platelet-rich plasma signiﬁ  cantly 
accelerated ulcer healing
Wallace et al 2006
Chronic ulcer treatment At 8 weeks, the mean percentage of surface healed 
in the PRGF group was signiﬁ  cantly higher than in 
the control group (73% versus 21.4%) (P  0.05)
Anitua et al 2007
Bone regeneration in sinus ﬂ  oor augmentation Bone densitometric values and bone amount were 
higher in sites treated with PRP
Consolo et al 2007
Nerve regeneration The best results were obtained when the nerves 
were sutured and PRP was added to the sutures, 
showing a neurotrophic effect
Farrag et al 2007
Repair of chronic elbow tendinosis At ﬁ  nal follow-up (mean 25.6 months), PRP 
patients reported 93% reduction in pain compared 
with before the treatment
Mishra et al 2007
Repair of anterior cruciate ligament Collagen-PRP mixture resulted in signiﬁ  cant 
improvements in load at yield, maximum load, and 
linear stiffness at 4 weeks post-treatment
Murray et al 2007
Expansion of mesenchymal stem cells (MSCs) MSCs maintained their osteogenic, chondrogenic, 
and adipogenic differentiation properties and their 
immuno-suppressive activity
Doucet et al 2005
Dry eye symptoms Symptoms improved signiﬁ  cantly in 89% of the 18 
patients. Improvement on lachrymal meniscus and 
conjunctival hyperemia were observed
Alio et al 2007
Abbreviations: PRGF, preparation rich in growth factors; PRP, platelet-rich plasma; MSCs, mesenchymal stem cells. (For further details see Anitua et al 2007b).Neuropsychiatric Disease and Treatment 2008:4(6) 1075
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by a cohort of several trophic factors and other cytokines 
contained in young and healthy platelets (Table 2) (Anitua 
et al 2004, 2005, 2006, 2007b, 2008a) led us to introduce the 
concept of a general “trophic factor withdrawal syndrome” 
in recent publications of our group (Anitua et al 2007b; 
Harguindey et al 2007, 2008). Finally, since epigenetic and 
genetic factors can primarily inﬂ  uence the susceptibility 
to neurodegeneration, the implementation of personalized 
treatments based on pharmacogenetic principles are also 
acquiring an increasing importance in order to optimize the 
so far limited therapeutic resources nowadays available in 
these complex neurodegenerative disorders (Cacabelos 2005; 
Cacabelos et al 2006).
The trophic factor 
withdrawal syndrome (TFWS) 
in the etiopathogenesis of human 
neurodegenerative diseases (HNDDs)
Large scale apoptosis induced by trophic hormone withdrawal 
was ﬁ  rst reported in hormone-dependant tumors (Kerr et al 
1972). Microenvironmental depletion or functional inability 
of a wide array of growth factors whose stimulus is necessary 
for cell survival, such as insulin-like growth factor-1 (IGF-1), 
PDGF, VEGF, EGF, FGF, and neurotrophins like NGF or 
others (Barbin 1987; Desmuck et al 1997; Guo et al 1997; 
Counts et al 2000; Estévez et al 2000; Poser et al 2003; 
Chao et al 2006), apart from cytokines like interleukin-2 
(IL-2), IL-3, IL-7 (Khaled et al 2001), a downregulated 
Bcl-2 (Shacka et al 2005), or an upregulated p53, etc., is 
sufﬁ  cient to induce massive neural cell apoptosis (Rebollo 
et al 1995; Tatton et al 2003) (Table 3). In the central 
nervous system (CNS), a functional deﬁ  ciency of certain 
growth factors in the microenvironment can be secondary 
to: A) a systemic failure of growth factor production, this is, 
lack of availability; B) inadequate activity of certain trophic 
molecules in the cell membranes of target tissues of neural 
origin; C) transmembrane receptor down-regulation or bind-
ing deﬁ  ciency, and/or D) abnormalities in the intracellular 
signaling cascade. An altered function of any of these 
circumstances may have a key etiopathogenic role in the 
pathological cell death of different HNDDs (Politi et al 2001; 
Tatton et al 2002; Alvarez et al 2007; Corzo et al 2007; Ray 
et al 2007). Apoptotic or parapototic cell suicide can be 
initiated by removal of different growth factors, while trophic 
factor withdrawal is a key factor in inducing an apparently 
sine qua non intracellular acidiﬁ  cation that seems necessary 
in mediating the different cell death programs in both neural 
cells and cancer cells alike (Burns et al 1983; Vincent et al 
1999). Thus, the systematic clinical utilization of different 
GFs, alone or in combination, opens new possibilities in the 
prevention and treatment of HNDDs (Bröker et al 2005). This 
review is an exercise in both translational and transversal 
research between neurology, hematology, and oncology 
research in order to propose new pathways towards a better 
understanding of the pathogenesis of HNDDs to discover 
new therapeutic approaches through the clinical utilization 
of GFs and other similar measures in both the prevention and 
treatment of these processes.
Mediating mechanisms 
in the pathogenesis of HNDDs. 
The universal role of Na+/H+ 
exchange and intracellular pH 
in the action of growth and trophic 
factors. Cellular Darwinism 
and the law of speciﬁ  city 
and nonspeciﬁ  city in biology
The role of Na+/H+ exchange 
and intracellular pH as universal 
mediators and in the activation 
and inhibition of growth and trophic 
factors in HNNDs and cancer
Some of the main areas of cancer research, from 
etiopathogenesis to treatment at both the basic and clinical 
levels (malignant transformation, growth and proliferation, 
cell migration, angiogenesis, the metastatic process, 
Table 2 Growth factors contained in normal platelets
Growth factors Function
PDGF, TGF-b1 and-2, EGF, VEGF (A y C) Chemotaxis, cell proliferation
bFGF; HGF, BMP-2, -4, -6, CTGF Cell trophism, coagulation, angiogenesis, etc.
Abbreviations: PDGF, platelet-derived growth factors; TGF-b1 and -2, transforming growth factor; EGF, epidermal growth factor; VEGF, vasoendothelial growth factor; bFGF, 
ﬁ  broblastic growth factor; HGF, hepatocyte growth factor; BMP-2, -4, -6, bone morphogenetic protein; CTGF, connective tissue growth factor. (For further details see Anitua 
et al 2004).Neuropsychiatric Disease and Treatment 2008:4(6) 1076
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multiple drug resistance to chemotherapy (MDR), oncogene 
expression, growth factor activity, tumor glycolysis, cell 
cycling, DNA synthesis, apoptosis, etc.), have been recently 
integrated under an Unitarian perspective based upon 
the dynamics of the hydrogen ion and Na+/H+ antiporter 
(Harguindey et al 2005). Similar aspects of cancer have lead 
some researchers to consider that “cancer Achilles’s heel” 
can hide within the frame of H+ dynamics and its second-
ary effects on cellular metabolism (J. Poúyssegür, personal 
communication). Furthermore, the most active proton pump 
inhibitors (PPI) of the amiloride series and beyond, increas-
ingly appear as cancer “magic bullet” because their selective 
potential to induce a selective metabolic collapse and cell 
death, apoptosis-mediated or otherwise, of cancer cells and 
tissues irrespective of origin and cell lineage (Rich et al 2000; 
Torigoe et al 2002; Izumi et al 2003; Harguindey at al 2005; 
Poüyssegúr et al 2006).
While human and trophic growth factors have different 
origins and speciﬁ  c target cells, their mediating mechanisms 
of action at the level of the cell membrane and intracellular 
signaling show common final pathways in all kinds of 
cells (Harguindey et al 2008). First, pro- and antiapoptotic 
intracellular signaling pathways are already known to a 
considerable extent, and maps of those intracellular pathways 
as possible therapeutic targets in different pathologies are 
already available (Hanahan 2000; Reed 2004; Lavrik et al 
2005). Secondly, we have learned from experimental and 
translational oncology research that a key feature mediating 
the molecular mechanisms of action in the stimulation by the 
majority of, if not all, growth factors, is an increase in the 
rate of exchange of Na+ and H+. An over-expressed extrusion 
of H+ ions, which is mainly mediated by the membrane-
bound Na+-H+ exchanger, induces an intracellular (IC) 
alkalinization and the disruption of both the IC–extracellular 
(EC) homeostasis of the cell (Burns et al 1983; Moolenar 
et al 1983; Harguindey et al 1995, 2005; Reshkin et al 2000, 
2003; Khaled et al 2001; Harguindey 2003; Orive et al 2003; 
Cardone et al 2005; Di Sario et al 2007). This phenomenon 
is recognized as a key and speciﬁ  c feature not only in malig-
nant cell transformation but also in the growth and invasion 
of cancer cells of all lineages and origins, as well as in the 
activation the metastatic process, through the creation of an 
abnormal IC–EC proton gradient (the so called “H+-gradient 
reversal”) (Belaud-Rotureau et al 2000; Reshkin et al 2000; 
Khaled et al 2001; Cardone et al 2005; Harguindey et al 
2005; Poüysségur et al 2006).
Table 3 Opposed trends of apoptotic-related parameters and therapeutic directions in human neurodegenerative diseases (HNDDs) 
and cancer
HNDDs (Alzheimer’s disease, etc) Cancer
Factors involved:
Apoptosis ↑ (pro-apoptosis, pathological) ↓ (antiapoptosis, pathological)
Trophic factors ↓↑
Caspase activity ↑↓
Bax activity ↑↓
p53 activity ↑↓  (or mutated)
Bcl-2 ↓↑
Na+/H+ exchanger ↓ (?) ↑
pHi ↓↑
Oxidative stress ↑↓
Therapeutic directions
GFs To stimulate (PDGF,   VEGF, NGF) To inhibit (IDN-5370, z-VAD-fmk)
Caspases To inhibit To stimulate
c-Jun protein kinase To inhibit To stimulate
Apoptosis To inhibit To stimulate
(antiapoptosis) (pro-apoptosis)
Antioxidants Indicated Contraindicated (?)
Na+/H+ Antiporter To stimulate (Bcl-2, cloroquine, imidazole, 
GFs (G-CSF, PDGFs, etc.):
Platelet transfusions
To inhibit (amiloride, Il-2, LAK, 
lovastatin, squalamine, staurosporine, 
etc.)
Note: For further details see Harguindey et al 2007.Neuropsychiatric Disease and Treatment 2008:4(6) 1077
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The NHE, mainly the NHE-1 isoform, plays an essential 
and pivotal role in the IC signal transduction pathways of a 
multiplicity of different hormones, membrane signals, as well 
as trophic and growth factors (for a review, see Harguindey 
et al 2005). The stimulation of this ﬁ  nal common pathway 
by all the different kinds of mitogenic factors results in 
the activation of the Na+/H+ antiporter and its secondary 
induction of an elevation of intracellular pH (Burns et al 
1983; Di Sario et al 2001; Cardone et al 2005; Harguindey 
et al 2005). This phenomenon has been known for some 
time to represent an early and essential step in mediating 
cell proliferation and DNA synthesis (Burns et al 1983; 
Moolenar et al 1983; L’ Allemain et al 1984; Grinstein et al 
1989; Harguindey et al 1995; Reshkin et al 2000). Indeed, 
trophic and growth factors with clear-cut antiapoptotic 
activity always stimulate the NHE-1 and increase pHi, this 
being a fundamental homeostatic mechanism that protects 
cells against a pathological fall in pHi (Burns et al 1983; Di 
Sario et al 2007; Harguindey et al 2007). In this way, cell 
death programs, either through apoptosis and/or parallel 
mechanisms, can be counteracted (Table 4) (Rich et al 2000; 
Khaled et al 2001; Reshkin et al 2003; Harguindey et al 
2005). Among these antiapoptotic–antiacidiﬁ  cation factors 
are the Bcl-2 family, Bax deletion, certain oncogenes, a 
dysfunctional p53 suppressor gene, etc. (DiGiammarino 
et al 2000; Marches et al 2001; Thangaraju et al 2001). The 
main bulk of available literature points to the conclusion that 
cellular neuroprotection is also mediated by a pHi-sustaining 
effect on IC metabolism and homeostasis of an acid-base 
nature (therapeutic antiapoptosis) (Vincent et al 1999), in a 
similar manner that the survival mechanisms described for 
cancer antiapoptosis, mainly in multiple drug resistance to 
chemotherapy (MDR) (pathological antiapoptosis) (Hamilton 
et al 1993; Roepe et al 1993; Gottlieb et al 1996; Vincent et al 
1999; Simon 2000; Harguindey et al 2005). Most signiﬁ  -
cantly, in trophic under-stimulation and/or in growth factor 
deprivation the cell signals to detect IC acidiﬁ  cation appear 
to be the same ones as for spontaneous apoptosis (Hamilton 
et al 1993; Roepe et al 1993; Gottlieb et al 1996; Furlong et al 
1997; Famulski et al 1999; Park et al 1999; Thangaraju et al 
1999; Belaud-Rotureau et al 2000; Matsuyama et al 2000; 
Rich et al 2000; Di Sario et al 2001; Marches et al 2001; 
Simon 2001; Lagadic-Gossmann et al 2004; Di Sario 2007) 
(Figure 1). In this line, antiapoptotic Bcl-2 or a deleted 
pro-apoptotic Bax protein have been shown to directly prevent 
cellular acidiﬁ  cation and thus, cellular injury (Park et al 1999; 
Thangaraju et al 1999; Belaud-Rotureau et al 2000; Brodski 
et al 2002; Tafani et al 2003). This IC homeostatic acid-base 
approach opens new possibilities in the strategy to implement 
new preventive and/or therapeutic measures in HNDDs, hitting 
as a key and pivotal therapeutic target pHi homeostasis with 
any drug or biological compound that, alone or in combination 
(imidazole, chloroquine, neurotrophic or other growth factors, 
Bcl-2, cytokines, oncogenes, cell proteins, gene products, 
platelet transfusions) that activate the NHE-1 and/or decrease 
nitric oxide (NO) production, thus sustaining pHi within normal 
limits and allowing IC proton homeostasis and cell function as 
a whole to be kept within a physiological range (Table 3).
Parallel processes of the pathological 
apoptosis in HNDDs and the over-
coming of the resistance to apoptosis 
(pathological antiapoptosis) in cancer 
therapeutics
What spontaneously takes place in HNDDs (pathological 
apoptosis) (Raina et al 2003), is the same phenomenon that 
cancer therapeutics attempt to selectively induce through a 
wide array of different approaches and methods (therapeutic 
apoptosis) (Figure 1). Similarly, it has been shown that one 
of the main mechanisms by which cancer cells are resistant to 
chemotherapeutic treatment (MDR) is secondary to the fact 
that most cancer cells posses concerted defensive mechanisms 
that allow them to maintain their intracellular acid-base 
situation well above normal levels through all kinds of damag-
ing microenvironmental circumstances. This has been called 
“the neostrategy of cancer cells and tissues” (Harguindey et al 
2005). Otherwise, a successful treatment in cancer is mediated 
by the activation of a low pHi-mediated apoptotic chain reac-
tion cascade ending in cancer cell death (therapeutic apop-
tosis) (Famulski et al 1999; Park et al 1999; Williams et al 
1999; Harguindey et al 2005; Di Sario et al 2007; Letai 2008). 
Some of these mechanisms are mediated by executionary 
caspases or by the therapeutic activation of a JNK apoptotic 
pathway in cases of successful chemotherapy (Perona et al 
2007). Most interestingly, a parallel phenomenon, namely, an 
oxidative stress-mediated activation of the c-Jun -N-terminal 
kinase, takes place in AD (see Figure 1). Furthermore, 
JNK activation is also mediated by directly inducing a low 
pHi and by amiloride treatment (Lachapelle et al 2007). 
Table 4 pHi, apoptosis and antiapoptosis in HNDDs and cancer
HNDDs Cancer
↑ pHi Therapeutic antiapoptosis Pathological antiapoptosis
↓ pHi Pathological apoptosis Therapeutic apoptosisNeuropsychiatric Disease and Treatment 2008:4(6) 1078
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Other mechanisms of successful cancer treatment include 
overcoming blockades to cancer cell apoptosis by inhibiting 
the Bcl-2 antiapoptotic family, whose activity is not surpris-
ing that is mediated by IC alkalinization and inhibited by cell 
acidiﬁ  cation (Reynolds et al 1996; Yang et al 1997; Ishaque 
et al 1998; Shimuzu et al 1998; Zanke et al 1998; Zhiuza et al 
1998; Thangaraju et al 1999; Matsuyama et al 2000; Takashaki 
et al 2004; Waibel et al 2007). Resistance to chemotherapy 
(MDR) can also be achieved by similar pH-related methods 
(Roepe et al 2001; Harguindey et al 2005). A large deal of 
accumulated data in this area indicates that the study of Bcl-2 
as an antiapototic agent seems secondary to an alkalinizing 
pHi effect, another feature that can be integrated within the 
H+-mediated model (Reynolds et al 1996; Thangaraju et al 
1999; Matsuyama et al 2000). This makes it highly surprising 
that even the more recent reviews on cell death mechanisms 
and resistance to them, either in cancer and HNDDs, either 
completely ignore the dynamics of the hydrogen ion in these 
situations or they are granted a meaningless secondary role 
at the most (Raina et al 2003; Waldeimer 2003; Reed 2004; 
Szakátz et al 2006). Even more, malignant cell apoptosis 
can be selectively induced by proton pump inhibitors (PPI) 
APOPTOSIS 
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+/H
+ antiporter 
 H
+- ATPasa  
Caspases 8,  9 SHP-1   SST  
DNA fragmentation   Bax proteins, MAPK, JNK, etc. 
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Figure 1 Relationships among intracellular signaling factors, pHi, and apoptosis.
Abbreviations: ↑, stimulation; ↓, inhibition; ST, somatostatin; SMP-1, tyrosinephospatase; MDR, multiple drug resistance; GFs, growth factors; Cyt C, cytochrome C; NO, nitric 
oxide; TFWS, Trophic factor withdrawal syndrome.
Notes:  For further details see Rideout et al 2001; Reed 2002, 2004; Waldeimer 2003; Waldeimer et al 2004; Broker et al 2005; Harguindey et al 2007.Neuropsychiatric Disease and Treatment 2008:4(6) 1079
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like HMA (5-(N, N-hexamethylene)-amiloride) (Rich et al 
2000), or acid-mediated stimulation of p53 (Williams et al 
1999) (Table 4 and Figure 1).
Multiple drug resistance to different chemotherapeutic 
agents (MDR) can be overcome by HMA or other PPI of 
the amiloride series, another low pHi-mediated phenomena 
(Roepe et al 2001; Harguindey et al 2005; Miraglia et al 
2005, Di Sario et al 2007). In summary, all the available 
evidence indicates that the more reductionistic and 
fragmented model represented by the detailed study of any 
individual factors as well as the intricate abnormalities of 
the intracellular signaling pathways can be inserted within a 
more comprehensive and integral homeostatic paradigm of 
an acid-base nature as represented by the IC–EC dynamics 
of the hydrogen ion (H+). This acquires further signiﬁ  cance 
when attention is paid to the fact that the dynamics of proton 
movements in and out of the cell and its transmembrane 
gradients seem to be the ultimately responsible factor and 
mechanism for the apoptosis-antiapoptosis machinery in 
both HNDDs and cancer (Gottlieb et al 1996; Furlong 
et al 1997; Famulski et al 1999; Park et al 1999; Vincent 
el al 1999; Williams et al 1999; Harguindey et al 2000, 
2005, 2007; Matsuyama et al 2000; Raina et al 2003; Tafani 
et al 2003; Waldeimer 2003; Lagadic-Gossmann et al 2004; 
Reed 2004; Letai 2008).
In spite that cancer cells seem able to evade apoptosis 
by trophic factor deprivation in many cases (Tang et al 
1998; Thompson et al 2005), antihormonal and antigrowth 
factors are being tried in different therapeutic attempts in the 
oncology setting (Shegal et al 1994; Taetle et al 1994). These 
and other parallel considerations relating H+ dynamics and 
GF activity allow to place the biochemistry and molecular 
biology of HNDDs and cancer at both ends of an apoptotic-
antiapoptotic metabolic spectrum (Harguindey et al 1992b, 
2007) (Tables 3 and 4). The same unitarian perspective that 
has made possible to integrate the main areas of basic and 
clinical oncology research (Harguindey 1992a; Harguindey 
et al 1995, 2005), now allows to advance another new concept: 
that what is pathological and damaging for some diseases 
(the spontaneous apoptosis of HNDDs) can be therapeutic 
and beneﬁ  cial for their metabolic and homeostatic opposites 
(the antiapoptosis of malignancy) (Table 4). Thus, a primor-
dial approach to IC homeostasis may open new and untrodden 
ways towards entirely new therapeutic approaches, aiming 
at the Na+/H+ antiporter, other membrane proton pumps 
and NO production and control as primordial therapeutic 
targets, either in the induction of selective low pH-mediated 
apoptosis in cancer treatment through the utilization of 
proton transport inhibitors (therapeutic apoptosis) or, in the 
opposite direction, counteracting IC acidiﬁ  cation in HNDDs 
(therapeutic antiapoptosis) (Troy et al 1996; Rich et al 2000; 
Torigoe et al 2002; Izumi et al 2003; Harguindey et al 2005; 
Poüysségur et al 2007).
Terminal pathogenesis of apoptotic 
or para-apoptotic cell death in HNDDs. 
NO, oxidative stress, and cellular pHi
When deprived of trophic factors (TFWS), motor neurons 
undergo a programmed cell death program, apparently through 
nitric oxide-dependent apoptosis (Hirakura et al 1999; Vincent 
et al 1999; Estévez et al 2002; Wilkins et al 2004; Estévez 
et al 2006), and/or superoxide production (Lieberthal et al 
1998) and/or caspase activation (Troy et al 1996; McCarthy 
et al 1997; Chan et al 1999; Deshmukh et al 2000; Choi et al 
2002). The induction of NO-related mechanisms share a 
common ﬁ  nal pathway that involves nitric oxide synthase 
(NOS) and peroxynitrite formation. NO has been linked, partly 
because to its oxidative role, to the development of several 
neurodegenerative disorders, seemingly by activating a pHi-
related apoptotic cascade (Corzo et al 2007). Furthermore, 
the formation of NO by astrocytes has been suggested to 
contribute to the neurodegenerative process, while NO pro-
duction is signiﬁ  cantly elevated in platelets from AD patients 
(Fernandez-Vizarra et al 2004). This very same mechanism 
proves to be of value in inducing apoptosis, via necrosis, in 
neoplastic cells (Rigas et al 2008) (Table 3).
The seminal work of Vincent and colleagues (1999) in 
neurons has shown that lowering pHi from 7.36 to 7.09/7.00 
through exposure to NO sets in motion a programmed cell 
death (PCDP) program, increasing DNA fragmentation and 
decreasing neuronal survival (low pHi-mediated metabolic 
collapse). This phenomenon is induced by the activation 
of three low pHi-dependent endonucleases responsible for 
neuronal injury (Figure 1). Furthermore, the formation of pHi-
lowering pro-apoptotic NO by astrocytes suggests a potential 
for NO inhibitors in the treatment of this disease, most likely 
through the stabilization of IC acid-base homeostasis and 
the prevention of a deadly drop in pHi (Harguindey et al 
2003; Arianna et al 2007) (Figure 1). Other compounds 
with different anti-NO properties like superoxide dismutase, 
minocycline, NGF, etc, have also shown neuroprotective 
effects (Kirkland et al 2003; Wilkins et al 2004; Estévez et al 
2006). The stimulation of oxidative stress by NO has been 
involved in the pathogenesis of dementia (Corzo et al 2007), 
while oxidative stress and/or reactive oxygen species (ROS) 
have been widely considered as a key factor in neuronal Neuropsychiatric Disease and Treatment 2008:4(6) 1080
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degradation (Harguindey et al 2007). Superoxide (SO) 
formation induced by growth factor deprivation induces 
apoptosis (Lieberthal et al 1998). This phenomenon is further 
increased after reacting SO with NO to form peroxynitrite 
(Estévez et al 2006). In contrast, low or physiological 
concentrations of NO prevents apoptosis (Choi et al 2002). 
In summary, the dynamics of the killing mechanism (see 
also Figure 1), are:
↑NO (+/− SO) → ↓pHi → ↑Cytochrome C release →
↑Cytosolic caspases and endonucleases → NEURAL 
CELL DEATH
The study of the molecular biology of cancer cells has 
shown that the inhibition of the electroneutral membrane 
exchanger NHE-1 induces intracellular acidiﬁ  cation by 
entrapping hydrogen ions within the cell (Li et al 1995; 
Rebollo et al 1995; Harguindey et al 2003). A severe 
intracellular acidosis below a certain threshold (pHi: ± 6.8) 
is an essential factor in setting up a cascade-like chain reac-
tion ending up in the metabolic collapse preceding apopto-
sis, either in cancer cells (therapeutic apoptosis) (Rich et al 
2000, Di Sario et al 2007) or in dying cells of neural origin 
(pathological or degenerative apoptosis) (Figure 1) (Hamilton 
et al 1993; Roepe et al 1993; Gottlieb et al 1996; Harguindey 
et al 1995; Li et al 1995; Rebollo et al 1995; Park et al 1999, 
2005; Vincent et al 1999; Thangaraju et al 1999; Matsuyama 
et al 2000; Rich et al 2000; Di Sario et al 2001; Simon 2001; 
Wahl et al 2002; Lagadic-Gossmann et al 2004).
Cellular Darwinism. The law of speciﬁ  city 
and nonspeciﬁ  city in biology
From the point of view of biological evolution, the simplest 
way (and to follow Darwinian rules nature always chooses 
the simplest possible way in order to solve its biological 
problems and preserve the stability and continuation of life) 
is that a wide array of trophic, growth factors and hormones 
have different kinds of target cells with speciﬁ  c receptors 
for different cell lineages. This represents a qualitative and 
speciﬁ  c variation. At the same time, cellular physiology 
has a very small number of transduction mechanisms from 
the membrane to the interior of the cell to inﬂ  uence intra-
cellular signaling pathways that are shared by all kinds of 
cells. These mechanisms may only vary from one another 
in some quantitative, nonspeciﬁ  c aspects. The procedure of 
choosing the kind of response is through a selective, however 
variable distribution of speciﬁ  c receptors in the different 
cell lineages concerted with a few number of membrane-
bound signals, as the family of the proton pump transporting 
systems, and from there on to mostly shared IC signaling 
pathways. This is the simplest possible way that can be 
imagined. Much more difﬁ  cult would be that nature would 
have chosen that all cells would have the same or similar 
receptors. Should this have been the case, all cells would 
be equally sensitive to all different kinds of stimulating or 
inhibiting hormones and growth factors in order to induce 
numberless and different effects in each cell or cell lineage. 
In this case it would have been necessary to select the kind 
of response through a great number and diversity of signals 
and/or intracellular transduction mechanisms in the different 
cells and/or lineages. This complication is so great that it 
rules itself out. It is much more logical that evolution selects 
target cells providing them with speciﬁ  c receptors, which 
are the mediating mechanisms responsible for selecting the 
kind cellular response, than to have numberless IC signaling 
factors and pathways for each lineage or cell (Meléndez 
Hevia 2001; Harguindey et al 2008). In this way, a countless 
diversiﬁ  cation of effects is reduced to the qualitative and 
quantitative distribution of membrane receptors, which would 
decrease the information and stimulus-response systems of 
cells to the smallest number and the least possible degree 
of complication. All the above-mentioned features can be 
represented through the following scheme:
Systemic  Cell membrane  Intracellular 
circulation   signaling
Multiplicity   Speciﬁ  city of    Similar IC
of stimulus  receptors (qualitative) pathways 
(hormones, Same  electro-  (quantitative/
FC, etc.) chemical  nonspeciﬁ  c)
 mechanisms 
The fact that all the different kinds of cells of living organ-
isms and a multiplicity of mitogenic stimuli, hormones and 
growth factors share the same universal transport systems, 
mainly the Na+/H+ antiporter but also a few other membrane-
bound proton pumps at the cell membrane (Harguindey et al 
2005), allows to formulate a law that uniﬁ  es and combines 
speciﬁ  city and nonspeciﬁ  city in biology. Similar examples of 
this law at the level of intermediary metabolism, are:
a)    Glucose transporters sensitive to insulin (GLUT 4), that 
are only present in fat, muscle, and heart tissues.
b)  Adrenalin receptors for the stimulation of glucogenolysis, 
that are only present in muscle and liver.
c)    Glucagon receptors for glucogenolysis, only present in 
liver.
In all these cases, the mechanism of intracellular stimulation 
is always the same one: activation of adenylate cyclase to Neuropsychiatric Disease and Treatment 2008:4(6) 1081
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produce cAMP) (Meléndez Hevia 2001). If we apply this law 
to neuronal neuroprotection, any trophic factors with a clear-
cut antiapoptotic activity also stimulate the NHE-1 exchanger 
(Moolenar et al 1983; L’ Allemain et al 1984). Among the 
different membrane-bound proton pumps, the NHE1 appears 
to be the main homeostatic mechanism that protects cells 
against a pathological decrease in pHi and so, against cell death 
through cytosolic acidiﬁ  cation. Thus, in many cases cellular 
protection seems to be ultimately mediated by a pHi-sustaining 
effect responsible for a physiological equilibrium and intracel-
lular homeostasis of an acid-base nature. We have called this 
phenomena “therapeutic antiapoptosis”, a parallel concept 
to the “pathological antiapoptosis” which is characteristic 
to cancer cells, mainly in cases of multiple drug resistance 
to antichemotherapuetic agents (MDR) (Roepe et al 2003; 
Harguindey et al 2008) (Table 4). In summary, a primordial 
approach to the dynamics of cellular proton homeostasis gives 
way to new therapeutic possibilities, strategies and targets both 
in the treatment of HNDDs and neoplastic diseases (Rich et al 
2000; Harguindey et al 2005, 2007).
The pHi factor and platelet 
abnormalities in AD.   Therapeutic 
possibilities of human growth 
factors in the treatment 
of the trophic factor withdrawal 
syndrome in HNDDs
Intracellular homeostasis.   The pHi factor
The ﬁ  nal common pathway mediating cellular responses 
to different mitogenic stimulus, growth factors and other 
membrane signals such as hormones, has been repeatedly 
recognized to be secondary to the induction of an elevation 
of pHi (Burns et al 1983; Moolenar et al 1983; L’ Allemain 
et al 1984; Harguindey et al 1995; Cardone et al 2005). 
Contrariwise, apoptosis, either in HNDDs or other settings, 
is largely mediated by IC acidiﬁ  cation (Vincent et al 1999; 
Harguindey et al 2005). Contrariwise, maintaining IC 
alkaline levels at the level of pHi = 7.60 prevents neuronal 
injury, not only implying pHi as a critical factor in PCD 
but also indicating a possible role for therapeutic cellular 
alkalinization in the prevention and treatment of neuronal 
degeneration, as shown by Vincent and colleagues (1999). 
These authors and others (Harguindey et al 2007) have 
concluded that counteracting a drop in pHi through trophic 
and/or peptide growth factors is a most attractive therapeutic 
target against neuronal degeneration and pathological death. 
Furthermore, inhibiting NO production by NO inhibitors, 
like mefenamic acid and thiadiazolidinones, and so IC 
acidiﬁ  cation, has been correctly proposed as a therapeutic 
option in the treatment of AD (Vincent et al 1999; Arianna 
et al 2007; Harguindey et al 2007). Thus, beyond multiple 
etiological causes and early EC factors that can be involved, 
a universal mechanism of an acid-base nature appears to 
be the pivotal and key event in downregulating caspase-
mediated or caspase-independent IC signaling pathways 
leading in many cases to cell death in HNDDs and, similarly, 
in different lineages of cancer cells (Hamilton 1993; Li et al 
1995; Pérez-Sala et al 1995; Rebollo et al 1995; Gottlieb 
et al 1996; Reynolds et al 1996; Furlong et al 1997; Hirakura 
1999; Park et al 1999, 2005; Vincent et al 1999; Thangaraju 
et al 1999; Williams et al 1999; Liu et al 2000; Matsuyama 
et al 2000; Rich et al 2000; Hirpara 2001; Marches et al 2001; 
Renz et al 2001; Reshkin et al 2003; Lagadic-Gossmann 
et al 2004; Riedl et al 2004; Vagheﬁ   et al 2004; Lavrik et al 
2005; Bredesen et al 2006, Di Sario et al 2007) (Figure 1). 
In summary, any therapeutic effort to keep IC acid-base 
homeostasis within normal or higher than normal levels, 
is likely to be of signiﬁ  cant beneﬁ  t in the prevention and 
treatment of HNDDs.
Platelet abnormalities in AD: 
Interdisciplinary hematology 
to neurology transversal research
Evidence for a role of platelet dysfunction, structural to 
functional, in AD patients arises from different studies 
(Zubenko et al 1987a, 1987b). Arianna and colleagues 
(2007) and Corzo and colleagues (2007) have reported 
that abnormal platelet function related to an increase 
in NO-producing systems play an important role in the 
pathogenesis of AD and in neuronal degeneration. From the 
structural side, the presence of abnormal coated-platelets 
with the capacity to retain amyloid precursor protein in their 
surface has been shown in early stage AD and MCI (mild 
cognitive impairment), a feature that also shows a signiﬁ  cant 
relationship with disease progression (Prodan et al 2007). 
Such abnormalities directly relate platelet abnormalities 
with the pathogenesis of at least some HNDDs, while at the 
same time they suggest that the supply of healthy exogenous 
platelets with high contents of PDGF and other platelet-
derived GFs may have a signiﬁ  cant therapeutic effect in at 
least certain HNDDs like AD (Figure 1 and Table 2).
Growth factors in neuronal protection
If one of the main trophic factors that stimulate growth 
and metabolism of muscle cells is plain exercise, the Neuropsychiatric Disease and Treatment 2008:4(6) 1082
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nervous system is stimulated by certain GFs, neurotrophic, 
platelet-derived, and beyond. The lack of cell trophism in 
different degenerative diseases makes it highly advisable to 
undertake clinical studies to detect the presence, decrease or 
even absence of either systemic, microenvironmental and/or 
cellular growth factors and other antiapoptotic substances 
(PDGF, VEGF, NGF, tyrosine kinases, Bcl-2, Bcl-X, etc.), 
not only in HNDDs but also in other systemic and nonneural 
degenerative diseases (Table 1) (Rideout 2001; Waldeimer 
et al 2003; Waldeimer 2004; Anitua et al 2005, 2006, 2007a, 
2007b, 2008a, 2008b; Wallace et al 2006; Farrag et al 2007). 
Ultrastructural-morphological studies and determinations of 
the content and activity of α-granules in platelets of patients 
with HNDDs, as well as measuring the concentration of the 
different PDGFs in the platelets of patients with AD and 
other HNDDs represent an unexplored ﬁ  eld of research that 
may lead to improving the understanding of the pathogenesis 
of HNDDs (Solerte et al 2005). In order to do this, the 
technology necessary to perform these measurements is now 
available (Anitua et al 2007a, 2007b).
Among the different PDGF, recent evidence points to 
a pivotal role for VEGF in neuronal protection (Jin 2002; 
Cao et al 2004; Storkebaum et al 2004a, 2004b; Solerte 
et al 2005). Decreased VEGF activity has been shown in 
different HNDDs. Recently, serum VEGF levels of patients 
with AD were compared with control subjects (Mateo et al 
2007). The mean concentration of VEGF in the patient group 
was signiﬁ  cantly lower than in the controls. These authors 
concluded that a decrease in serum levels of VEGF could 
contribute to the neurodegenerative process in AD. While no 
differences in serum VEGF levels between AD patients and 
controls have been found in other studies, low VEGF activity 
has also been reported in patients with ALS (Del Bo et al 
2005). The VEGF deﬁ  ciency trophic effect can be related to a 
decrease of VEGF secretion from coated-platelets secondary 
to already described abnormalities related to the retention 
of APP protein on their surface (Arianna et al 2007; Prodan 
et al 2007). Other authors have found co-accumulation of 
VEGF with ß-amyloid in AD, as well as a strong binding 
of VEGF to it, suggesting that secondary VEGF deﬁ  ciency 
under hypoperfusion may contribute to neurodegeneration 
and vascular dysfunction in the progression of AD (Del Bo 
et al 2005).
A decreased secretion and release of VEGF in the 
supernatants of circulating natural killer (NK) immune 
cells in patients with AD compared to normal controls and 
patients with other types of senile dementias has also been 
reported. This down-regulation of VEGF production has 
been demonstrated in peripheral immune cells of patients 
suffering from AD (Solerte et al 2005). These ﬁ  ndings 
become even more signiﬁ  cant when the pivotal importance 
of VEGF in brain angiogenesis, neuroprotection, and 
cerebrovascular exchange of nutrients is considered (Zhu 
et al 2002; Storkebaum et al 2004a; Yang et al 2004; Del 
Bo et al 2005; Solerte et al 2005) From a therapeutic point 
of view, direct application of VEGF delays the onset of 
paralysis, improves motor function and increases survival in 
a rat model of AD (Storkebaum et al 2004b; Vende Velde 
et al 2005). Since the highest known accumulation of VEGF 
can be found in platelets and leukocytes (Kut et al 2007), 
cyclic transfusions of healthy young platelets and, perhaps, 
leukocytes too, may represent the easiest and most natural 
available source of VEGF and other trophic growth factors 
and a signiﬁ  cant new therapeutic approach to certain HNDDs 
(Harguindey et al 2007).
Similarly, mice lacking epidermal growth factor receptor 
(EGFR) develop neurodegeneration through Akt-caspase 
dependent apoptosis of the frontal cortex (Wagner et al 2006), 
this representing a further example of neuronal degeneration 
as part of the trophic factor withdrawal syndrome (TFWS). 
Finally, the emerging role of other GFs, like FGF, mainly 
through its interaction with its receptors, has been reported 
to present a signiﬁ  cant role in brain neuronal trophism, repair 
and protection, and may also play a role in the treatment of 
certain mental disorders (Riva et al 2005).
The therapeutic potential of different neurotrophic factors 
in HNDDs has been studied for more than two decades (Hefty 
et al 1983; Varon et al 1987; Tatton et al 2003, Counts et al 
2005). Barbin (1987) initially showed that different neuro-
trophins induce growth and proliferation of cells of neural 
origin. The inhibition of NGF has been considered to be 
involved in the pathogenesis and treatment of the prodromal 
stages of AD (Tatton et al 2003; Counts et al 2005, Schulte-
Herbrügen et al 2008). However, more recent clinical trials 
using NGF have failed to show signiﬁ  cant results. Besides, 
the intracerebral local application of NGF faces many tech-
nical problems (Brodski et al 2002; Ebert et al 2005; Dass 
et al 2006). However, when glial cell line neurotrophic factor 
(GDNF) is infused via encapsulated cells in animal models 
of PD some positive results are obtained (Sajadi et al 2005). 
Furthermore, it has been reported that the local application 
of NGF into the putamen has produced sustained beneﬁ  ts 
in a small series of patients with PD (Slevin et al 2006). 
Other neurotrophic factors like pigment epithelium-derived 
factor (PEGF) protects retinal ganglion cells (Pang et al 
2007). Gene transfer factors and antiapoptotic promoting Neuropsychiatric Disease and Treatment 2008:4(6) 1083
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factors like Bcl-2 or other GFs have also been tried (Dass 
et al 2006; Sortwell et al 2007). Finally, hormones like thy-
rotrophin-releasing hormone (TRH) and its derivatives, as 
well as testosterone or estrogens, also play the role of GFs in 
protecting cells from neural injury in a similar manner than 
certain antioxidants like N-acetylcysteine (Yan et al 1995; 
Bialek et al 2004: Faden et al 2004). GFs besides VEGF 
and EGF, like IGF-1, whose deﬁ  ciency has also been related 
to the pathogenesis of AD (Alvarez et al 2007), are able to 
promote neural survival and differentiation (Politi et al 2001). 
Finally, different antiapoptotic therapies for neurodegenera-
tive diseases based upon the application of exogenous prod-
ucts that stimulate cell trophism, such as propargylamines, 
alpha-2-adrenergic receptor activators, minocycline, etc, are 
at the present time in preclinical stages of research (Tatton 
et al 2002, 2003; Lavrik 2005).
Use of PDGFs in clinical medicine 
and potential utilization of platelet 
transfusions in the treatment 
of HNDDs
One possibility of counteracting programmed cell death 
programs (PCDP) driven by deprivation of trophic and/or 
growth factors, would be to study the therapeutic potential of 
PDGF in HNDDs, as it has been recently tried in nonneural 
pathology (Lavrik 2005; Anitua et al 2007b; Ray et al 2007) 
(Table 1). Neurons, glial cells, and the pigmentary epithelial 
cells of the retina all contain platelet-derived growth factor 
receptors (PDGFR), making them classic therapeutic targets 
for PDGF. The cyclic administration of PDGFs in HNDDs 
through the exogenous supply of healthy platelets should 
be considered in a similar way that a wide variety of human 
pathologies are nowadays successfully treated through loco-
regional application of autologous platelet releseates obtained 
by simple clinical procedures (Fedi et al 1997; Anitua et al 
2004). This new research ﬁ  eld allows for important and excit-
ing new perspectives in opening untrodden areas of research 
and treatment of degenerative diseases, either from neural 
origin or otherwise, where a lack of one or more trophic 
factors is involved in their pathogenesis, including any kind 
of degenerative pathology where stimulation of new tissue 
growth or regrowth is necessary. Nowadays, clot preparations 
containing high concentrations of PDGF and metabolites that 
stimulate cell trophism, growth and proliferation, are being 
used with increasing frequency in a wide range of medical 
and surgical contexts apart from neurology, from dentistry 
and oral implantology to orthopaedics, gastric and skin ulcer 
treatment, eye disorders, etc, successfully inducing new tissue 
formation and accelerated tissue repair in different tissues and 
locations (Anitua et al 2004). Table 1 summarizes some of 
the therapeutic applications of platelet-based technology in 
modern clinical medicine. These platelet-releseates contain 
high concentrations of a wide array of mitogenic and pro-
angiogenic factors, mainly platelet-derived growth factor 
PDGF, TGF-ß1, EGF, VEGF, PDEGF, IGF-1, and HGF, 
as well as cytokines PF4 and CD40L, apart from lower 
concentrations of other factors like ß-FGF (Anitua et al 
2007b). Some of these factors show a potent stimulating 
effect on cell growth, proliferation and viability, to a large 
extent because of their positive effects on angiogenesis. The 
possibility of translating these successful clinical results to 
the prevention and treatment of HNDDs is one of the main 
medical challenges for the next few years.
Conclusions
The main conclusions of this study are:
a)  The exogenous utilization of human growth factors, 
platelet-derived or otherwise, present a therapeutic potential 
in the treatment of certain human neurodegenerative 
diseases (HNDDs).
b)  There is a large deal of both theoretical and experimental 
evidence, both at basic and clinical levels, to consider the 
cyclic and systemic use of healthy platelet transfusions 
in early stages of certain HNDDs like AD.
c)  The therapeutic failure in the prevention and treatment 
of HNDDs can be secondary to a certain extent to lack of 
knowledge about the implications of the different trophic 
factors in the pathogenesis of HNDDs within the frame 
of the TFWS.
d) Every effort to maintain intracellular acid-base 
homeostasis within the physiological range in HNDDs, 
thus preventing the metabolic collapse induced by cell 
acidiﬁ  cation and its secondary activation of cell death 
programs, will help to better understand, prevent and 
treat HNDDs.
e)  In the prevention and treatment of HNDDs, a more 
effective pharmacological inhibition of the formation of 
NO by neural cells is needed.
f)  Pathological and spontaneous programmed cell death 
programs in HNDDs, apoptotic or otherwise, are 
processes that dwell at opposite ends of an acid-base/
homeostatic spectrum when compared with the resistance 
to the induction of apoptotsis that characterizes malignant 
cells and tissues (pathological antiapoptosis).Neuropsychiatric Disease and Treatment 2008:4(6) 1084
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